EMA has issued recommendations for the influenza virus strains^1,2 that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2026.

Every year, EMA issues EU recommendations for the composition of seasonal influenza vaccines on the basis of observations by the World Health Organization (WHO), which are informed by regular monitoring activities on the prevalence and characteristics of different influenza viruses worldwide.

Manufacturers of live-attenuated vaccines or egg-based vaccines should include these three virus strains for the 2026/2027 season:

• an A/Missouri/11/2025 (H1N1)pdm09-like virus;
• an A/Darwin/1454/2025 (H3N2)-like virus;
• a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.

Manufacturers of cell-based vaccines should include these three virus strains for the 2026/2027 season:

• an A/Missouri/11/2025 (H1N1)pdm09-like virus;
• an A/Darwin/1415/2025 (H3N2)-like virus;
• a B/Pennsylvania/14/2025 (B/Victoria…